US-based synthetic biology company Calyxt has partnered with its manufacturing partner Evologic Technologies to further develop and scale its proprietary Plant Cell Matrix (PCM) technology platform.

The agreement is intended to drive a speed-to-scale approach to address the rising demand for sustainable ingredients across the cosmeceutical, pharmaceutical, and nutraceutical industries.

Under the terms of the deal, both firms will work to grow and scale Calyxt’s PCM technology.

Calyxt said that Evologic will back the manufacturing of its plant-based compounds and establish proof of concept for the scaling of various products for commercial production.

Calyxt president and CEO Michael Carr said: “This agreement is an important milestone in our speed-to-scale acceleration that will position us to address the growing interest in plant-based solutions across our target markets of cosmeceuticals, nutraceuticals and pharmaceuticals.

“Evologic shares our commitment to scaled and economically feasible solutions that will enable the accelerated growth of sustainable ingredients that are often difficult to source and finite in nature.

“We look forward to working closely with their talented team to deliver engineering innovations that help our target customers bring sustainable products to market.”

According to the plant-based synthetic biology company, the deal with Evologic will promote the development of plant-based synthetic biology capabilities further.

Based on its own bioprocess platform and technology, Evologic’s contract development and manufacturing services will assist Calyxt to produce bioproducts that are both unique and sustainable.

Evologic Technologies CEO and co-founder Wieland Reichelt said: “Since our founding, we have strongly supported the industry to turn science-based biological ingredients into economically feasible, industrial-scale products.

“Manufacturing is clearly the key for high product quality at reasonable costs even so for challenging plant based sustainable products.

“Through this agreement with Calyxt, we are excited to engage in changing the status quo of manufacturing plant-based solutions.”